Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

enrolled a total of forty-six heavily pre-treated multiple myeloma patients who had failed all other approved agents. Of 39 evaluable patients who received a dose of 20mg/m(2), 18 percent achieved an overall response and 26 percent achieved a clinical benefit response. An additional 41 percent achieved stable disease. Importantly, responses have also been sustained; patients achieving partial or minor responses stayed on therapy for a median treatment duration of 240 days, or approximately 8 months, and the median duration of response was 7.4 months. Ten percent of patients completed twelve cycles of treatment and an extension study has been initiated for patients who have stayed on drug for one year.

All patients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and were refractory to their last treatment. Eighty percent of patients received at least four prior treatments. Of 26 patients enrolled who were refractory to treatment with bortezomib, 19 percent achieved a clinical benefit response.

Carfilzomib was generally well tolerated and toxicities were manageable. The most common adverse events reported were fatigue, anemia and thrombocytopenia. Of note to this patient population, treatment with carfilzomib was associated with a low incidence of peripheral neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among patients with several co-morbidities.

These data were presented by Dr. Jagannath in an oral presentation titled "Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib in patients with relapsed and refractory multiple m
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... -- Cipla, a global pharmaceutical company which uses technology and ... today announced that its UK arm, Cipla EU has ... InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction ... $550 million and will be an all cash transaction. ... million for the year ended Dec 2014 and over ...
(Date:9/3/2015)... -- Report Details What can be expected ... to grow at the fastest rates? Visiongain,s brand new ... trends, opportunities and prospects there. Our 205-page ... most lucrative areas in the industry and the future ... sales at overall world market and regional level. You ...
(Date:9/3/2015)... a population of more than 1 billion, China is ... largest potential market for goods and services. In the ... economies in the average rate of growth in real ... an in vitro diagnostics (IVD) market, China trails only ... European countries, and Japan. China represents one of the ...
Breaking Medicine Technology:Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... MedMined(TM) services from Cardinal Health Equip Hospitals to Measure ... ... Sharing, DUBLIN, Ohio, April 29 Cardinal Health, a,global provider ... care, today announced a new benchmarking tool from,MedMined(TM) services that allows ...
... Opening celebrated with inaugural Symposium on Biofilms, ... 29 ,BASF today announced the official launch ... University. The Advanced Research Initiative at,Harvard University ... specifically to drive new frontiers of scientific,discovery. ...
Cached Medicine Technology:Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 2Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 3Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 4BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 2BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 3
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... and the surrounding communities, is launching a charity effort to provide for the ... referred to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships ... of cancer treatments and recover their mobility, strength, and range of motion following ...
(Date:9/4/2015)... ... September 04, 2015 , ... San ... available at CitiDent. CEREC is a newer method for creating restorations through innovative ... patients by eliminating the need for multiple appointments, CEREC produces restorations with total ...
(Date:9/4/2015)... ... 04, 2015 , ... Many consumers are looking for a quick and convenient way to produce ... patent-pending K Med Cups provide a quick and simple way to brew a hot cup ... or cough. As a result, they enhance comfort and health. The invention features a novel ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... Boston and Harvard Medical School will lead the efforts ... Office of the National Coordinator for Health Information Technology ... (HHS) to support research and development of a new ... of four awarded through the Strategic Health IT Advanced ...
... April 8, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... for Thursday, April 15, 2 3 p.m. Eastern ... Lawler & Lawler, with more than 30 years of ...
... an institute you can,t disparage." Especially, a new Tel Aviv ... prevent fatal strokes in men. The first study of ... its association with stroke risk,Prof. Uri Goldbourt of Tel Aviv ... in marriage and the likelihood that a man will die ...
... ... management client since 1994, was recently ranked among the top 100 hospitals in the United ... Top Hospitals® National Benchmarks Study were announced in the March 29 issue of Modern Healthcare. ... Brentwood, Tenn. (PRWEB) ...
... finds , THURSDAY, April 8 (HealthDay News) -- Although ... medical records as a major advance over the old paper ... haven,t significantly boosted patient life spans or lowered costs. ... health record adoption, and there,s little evidence for how best ...
... can benefit people with the disease , THURSDAY, April 8 ... diabetes in mice using a new vaccine technology that appears ... disease. , "The body has built-in mechanisms that try to ... can be [used] to selectively blunt an immune response without ...
Cached Medicine News:Health News:Boston researchers lead $15 million federal research grant to support advancement of health IT 2Health News:ACS Webinar focuses on immigration law for scientific professionals 2Health News:Different strokes for married folks? 2Health News:Thomson Reuters Names QHR Management Client to 100 Top Hospitals List - Wooster Community Hospital Honored for Third Consecutive Year 2Health News:Vaccine Reverses Type 1 Diabetes in Mice 2Health News:Vaccine Reverses Type 1 Diabetes in Mice 3
Hertel exophthalmometer...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
The first daily disposable lens affordable enough for full time wear....
... UltraPulse system's capability to quickly deliver up ... pulse allows for powerful single-pulse ablation. This ... system the coldest and cleanest CO2 surgical ... is combined with the independent adjustment of ...
Medicine Products: